Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
|Articles|June 4, 2021
Common Challenges in Cross-Functional Process Development
Author(s)BioPharm International Editors
Well-defined studies are crucial to effective process development.
Advertisement
In this interview with BioPharm International, James Blackwell, president of The Windshire Group, LLC, discusses stumbling blocks to process development; strategies for developing, scaling up, and scaling out bioprocesses; and challenges when working across multiple sites.
Advertisement
Related to this article
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
AbbVie's c-Met ADC Temab-A showed a 15.6% response rate in late-line colorectal cancer ahead of its 2 new FDA breakthrough designations.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
Advertisement
Advertisement